Skip to content

Research and optimization of the treatment of advanced gastric cancer with Chinese and Western medicine based on TCM tumor registration platform

Research and optimization of the treatment of advanced gastric cancer with Chinese and Western medicine based on TCM tumor registration platform

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038004
Enrollment
Unknown
Registered
2020-09-08
Start date
2020-09-25
Completion date
Unknown
Last updated
2020-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

Sponsors

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Pathologically diagnosed as gastric cancer; (2) TNM staged as stage IV; (3) Aged >= 18 years old, no gender limitation; (4) KPS >= 60; (5) Previously or currently receiving, or about to receive systematic traditional Chinese medicine treatment (oral decoctions prescribed by a traditional Chinese medicine oncologist using treatment based on syndrome differentiation method); (6) Volunteer to accept this study, sign the informed consent form, and complete the therapies and the follow-up once every 2 months, about 6 times in total, and willing to help the researchers collect relatively detailed clinical data.

Exclusion criteria

Exclusion criteria: (1) Suffering from two or more primary malignant tumors; (2) Suffering from serious non-neoplastic diseases and dysfunctions in important organs such as heart, lung, liver and kidney, or diagnosed as active cerebrovascular disease, uncontrolled infection and metabolic disease, neuropsychiatric disease or cognitive dysfunction, or other conditions with which patients can not complete the investigations;. (3) Unable or refuse to receive oral decoctions; (4) Expected survival is less than 3 months; (5) Existing other situations that are not suitable for participating in this clinical study, which is judged by our researchers.

Design outcomes

Primary

MeasureTime frame
overall survival;progression-free survival;

Secondary

MeasureTime frame
Response Evaluation Criteria in Solid Tumors;Karnofsky Performance Scale;MD Anderson Symptom Inventory;EORTC QLQ-C30 (V3.0) and QLQ-STO22 score;

Countries

China

Contacts

Public ContactHou Li

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

houli1203@126.com+86 13488695608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026